NCT05110196 - Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 3, 2022

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions

Non-Small Cell Lung Carcinoma

Interventions

DRUG

Capmatinib 150 mg

Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

DRUG

Capmatinib 200 mg

Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

Trial Locations (18)

110029

Novartis Investigative Site, New Delhi

125005

Novartis Investigative Site, Hisar

208020

Novartis Investigative Site, Kanpur

221005

Novartis Investigative Site, Varanasi

380016

Novartis Investigative Site, Gujarat

441108

Novartis Investigative Site, Nagpur

462001

Novartis Investigative Site, Bhopal

492099

Novartis Investigative Site, Raipur

500004

Novartis Investigative Site, Hyderabad

605006

Novartis Investigative Site, Puducherry

670103

Novartis Investigative Site, Thalassery

673008

Novartis Investigative Site, Kozhikode

700026

Novartis Investigative Site, Kolkata

751019

Novartis Investigative Site, Bhubaneswar

781023

Novartis Investigative Site, Guwahati

700 020

Novartis Investigative Site, Kolkata

695 011

Novartis Investigative Site, Kerala